OneSource Receives USFDA EIR with VAI Status for Bengaluru Sterile Facility
Onesource Specialty Pharma Ltd 路 Press Release 路 30 Oct 2026, 7:37 pm
OneSource Receives USFDA EIR with VAI Status for Bengaluru Sterile Facility OneSource Specialty Pharma Limited received the Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA on 30th Oct'26 for its Sterile Product Division (SPD) facility in Bengaluru. This successfully closes the regulatory inspection conducted between 22nd Jun'26 and 30th Jun'26. The clearance supports the company's sterile injectable capabilities and strengthens its CDMO platform across biologics, drug-device combinations, sterile injectables, and soft gelatin capsules.
Original exchange filing (PDF)
More announcements from Onesource Specialty Pharma Ltd
- Intimation of resignation of Senior Management Personnel 路 17 Nov 2026
- Onesource Specialty Pharma Limited has informed the Exchange about the Participation in Jefferies Global Healthcare Conference to be held from November 16, 2026 to November 19, 2026 in London. 路 05 Nov 2026
- Intimation of Transcript of Earnings call dated October 27, 2026 路 03 Nov 2026
- Intimation of the Audio recording of the earnings call pertaining to the unaudited financial results for the quarter and half year ended September 30, 2026 路 28 Oct 2026
- OneSource announces strong Q2FY27, results revenue up 37% YoY and EBITDA up 53% YoY 路 27 Oct 2026
- Intimation of allotment of 360 equity shares of Re.1/- each under ONESOURCE ESOP 2021 on October 27, 2026. 路 27 Oct 2026
- Intimation of change in designation of Dr. Claudio Albrecht from Independent director to Non-Executive Non-Independent Director of the Company. 路 27 Oct 2026
- Onesource Specialty Pharma Limited has submitted to the Exchange, the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. 路 27 Oct 2026
